Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    9
ATC Name B/G Ingredients Dosage Form Price
C10AA05 LIPONORM G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 967,567 L.L
C10AA05 LIPODAR G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 1,323,685 L.L
B05BB02 LO-SODIUM WITHOUT POTASSIUM INJECTION G Sodium dihydrogenophosphate - 0.137g/100ml, Sodium lactate (anhydre) - 0.223g/100ml, Sodium chloride - 0.0585g/100ml, Dextrose monohydrate - 5g/100ml Injectable solution 166,708 L.L
C10AA05 LORVAST G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 1,114,045 L.L
B05BB02 LO-SODIUM INJECTION G Sodium lactate - 0.223g/100ml, Sodium dihydrogenophosphate - 0.137g/100ml, Potassium chloride - 0.149g/100ml, Sodium chloride - 0.0585g/100ml, Dextrose, H2O - 5.0g/100ml Injectable solution 179,456 L.L
B05BB02 LO-SODIUM WITH POTASSIUM INJECTION G Potassium chloride - 0.149g/100ml, Sodium dihydrogenophosphate - 0.137g/100ml, Sodium lactate - 0.223g/100ml, Sodium chloride - 0.0585g/100ml, Dextrose monohydrate - 5g/100ml Injectable solution 165,727 L.L
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 541,863 L.L
G04BE08 LINK G Tadalafil - 20mg 20mg Tablet, film coated 1,374,751 L.L
G04BE08 LINK G Tadalafil - 20mg 20mg Tablet, film coated 369,557 L.L
N06AX21 LOXYT 60 G Duloxetine HCl - 60mg 60mg Capsule, delayed release 831,903 L.L
C10AA05 LIPONORM G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,249,774 L.L
J01MA02 LADININ G Ciprofloxacine (lactate) - 200mg/100ml 200mg/100ml Injectable solution 812,795 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
N06AX21 LOXYT 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
C10AA05 LIPODAR G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 2,236,154 L.L
N05AE05 LURABIL G Lurasidone - 20mg 20mg Tablet, film coated 2,535,831 L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard L.L
N05AE05 LURABIL G Lurasidone - 40mg 40mg Tablet, film coated 2,535,831 L.L
N05AE05 LAROZA G Lurasidone - 40mg 40mg Tablet, film coated 5,548,726 L.L
C10AA05 LORVAST G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,128,828 L.L
N05AE05 LURABIL G Lurasidone - 80mg 80mg Tablet, film coated 2,535,831 L.L
N06AX26 LYTIOX G Vortioxetine - 5mg 5mg Tablet, film coated 1,270,379 L.L
J01MA12 LEVOFLOXACIN NORMON G Levofloxacin - 500mg/100ml 5mg/ml Injectable solution 27,147,388 L.L
N05AE05 LAROZA G Lurasidone - 80mg 80mg Tablet, film coated 5,548,726 L.L
J01MA12 LEVOFLOX-MEDIS 500 G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 1,834,345 L.L
N05AE05 LAROZA G Lurasidone - 120mg 120mg Tablet, film coated 5,548,726 L.L
N06AX26 LYTIOX G Vortioxetine - 10mg 10mg Tablet, film coated 2,064,142 L.L
J01MA12 LEVOFLOXACIN- HAMELN G Levofloxacin - 500mg/100ml 5mg/ml Injectable solution 1,632,769 L.L
J01MA12 LOXAMOX G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 747,176 L.L
    ...
    9
Sitemap
© Copyrights reserved to Ministry of Public Health 2025